Neuronetics, Inc. Cost of Revenue
Neuronetics, Inc. (STIM) reported Cost of Revenue of $20.58 million for the 3-month period ending 2024-09-30, per its 8-K/A filed 2025-02-06.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2025-02-06
- Neuronetics, Inc. cost of revenue for the quarter ending 2024-09-30 was $20.58M, a 11.32% increase year-over-year.
- Neuronetics, Inc. cost of revenue for the quarter ending 2023-09-30 was $18.48M.
- Neuronetics, Inc. cost of revenue for the quarter ending 2020-12-31 was $3.76M, a 10.81% decline year-over-year.
- Neuronetics, Inc. cost of revenue for the quarter ending 2020-09-30 was $2.66M, a 36.62% decline year-over-year.
- Neuronetics, Inc. cost of revenue for fiscal 2018 was $12.45M, a 29.23% increase from fiscal 2017.
- Neuronetics, Inc. cost of revenue for fiscal 2017 was $9.63M, a 45.45% increase from fiscal 2016.
- Neuronetics, Inc. cost of revenue for fiscal 2016 was $6.62M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2024-09-30 | $20.58M 8-K/A · filed 2025-02-06 | $61.52M 8-K/A · filed 2025-02-06 | ||
| 2023-09-30 | $18.48M 8-K/A · filed 2025-02-06 | $57.17M 8-K/A · filed 2025-02-06 | ||
| 2020-12-31 | $3.76M 10-K · filed 2021-03-02 | $6.42M derived: sum of 2 quarters · filed 2021-03-02 | $8.74M derived: sum of 3 quarters · filed 2021-03-02 | $11.55M derived: sum of 4 quarters · filed 2021-03-02 |
| 2020-09-30 | $2.66M 10-K · filed 2021-03-02 | $4.98M derived: sum of 2 quarters · filed 2021-03-02 | $7.79M derived: sum of 3 quarters · filed 2021-03-02 | $12.01M derived: sum of 4 quarters · filed 2021-03-02 |
| 2020-06-30 | $2.32M 10-K · filed 2021-03-02 | $5.13M derived: sum of 2 quarters · filed 2021-03-02 | $9.35M derived: sum of 3 quarters · filed 2021-03-02 | $13.54M derived: sum of 4 quarters · filed 2021-03-02 |
| 2020-03-31 | $2.81M 10-K · filed 2021-03-02 | $7.03M derived: sum of 2 quarters · filed 2021-03-02 | $11.22M derived: sum of 3 quarters · filed 2021-03-02 | $15.39M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-12-31 | $4.22M 10-K · filed 2021-03-02 | $8.41M derived: sum of 2 quarters · filed 2021-03-02 | $12.58M derived: sum of 3 quarters · filed 2021-03-02 | $15.39M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-09-30 | $4.19M 10-K · filed 2021-03-02 | $8.36M derived: sum of 2 quarters · filed 2021-03-02 | $11.17M derived: sum of 3 quarters · filed 2021-03-02 | $14.88M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-06-30 | $4.17M 10-K · filed 2021-03-02 | $6.98M derived: sum of 2 quarters · filed 2021-03-02 | $10.69M derived: sum of 3 quarters · filed 2021-03-02 | $13.72M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-03-31 | $2.81M 10-K · filed 2021-03-02 | $6.52M derived: sum of 2 quarters · filed 2021-03-02 | $9.55M derived: sum of 3 quarters · filed 2021-03-02 | $12.80M derived: sum of 4 quarters · filed 2021-03-02 |
| 2018-12-31 | $3.71M 10-K · filed 2020-03-03 | $6.75M derived: sum of 2 quarters · filed 2020-03-03 | $9.99M derived: sum of 3 quarters · filed 2020-03-03 | $12.45M 10-K · filed 2019-03-05 |
| 2018-09-30 | $3.03M 10-K · filed 2020-03-03 | $6.28M derived: sum of 2 quarters · filed 2020-03-03 | $8.74M 10-Q · filed 2018-11-06 | $11.69M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | $3.25M 10-K · filed 2020-03-03 | $5.70M 10-Q · filed 2018-08-14 | $8.66M derived: sum of 3 quarters · filed 2020-03-03 | $11.29M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | $2.46M 10-K · filed 2020-03-03 | $5.41M derived: sum of 2 quarters · filed 2020-03-03 | $8.05M derived: sum of 3 quarters · filed 2020-03-03 | $10.55M derived: sum of 4 quarters · filed 2020-03-03 |
| 2017-12-31 | $2.96M 10-K · filed 2019-03-05 | $5.59M derived: sum of 2 quarters · filed 2019-03-05 | $8.09M derived: sum of 3 quarters · filed 2019-03-05 | $9.63M 10-K · filed 2019-03-05 |
| 2017-09-30 | $2.64M 10-K · filed 2019-03-05 | $5.14M derived: sum of 2 quarters · filed 2019-03-05 | $6.67M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $2.50M 10-K · filed 2019-03-05 | $4.04M 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $1.54M 10-K · filed 2019-03-05 | |||
| 2016-12-31 | $6.62M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |